Abstract
An emerging common feature of the age-associated neurodegenerative disorders like Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD) is the ability of many disease-associated protein aggregates to induce conversion of a normal counterpart conformer leading to an acceleration of disease progression. Curative pharmacotherapy has not been achieved so far despite successes in elucidating pathomechanisms. Here, we review the pharmaceutical strategy of generating hybrid compounds, i.e. compounds consisting of several independently acting moieties with synergistic effects, on key molecular players in AD and CJD.
For prion diseases, we review hybrid compounds consisting of two different heterocyclic compounds, their synergistic effects on prion replication in a cell culture model and their ability to prolong survival of experimentally prion-infected mice in vivo. While a combination therapy of several antiprion compounds including quinacrine, clomipramine, simvastatin and tocopherol prolonged survival time to 10-25%, administration of hybrid compound quinpramine alone, a chimera of acridine and iminodibenzyl scaffolds, led to 10% survival time extension.
For AD, we review a hybrid compound consisting of an A recognizing D-peptide fused to a small molecule -sheet breaker, an aminopyrazole. This molecule was able to diminish A oligomers in cell culture and significantly decrease synaptotoxicity as measured by miniature excitatory postsynaptic responses in vitro.
Hybrid compounds can dramatically increase potency of their single moieties and lead to novel functions when they act in a simultaneous or sequential manner thereby revealing synergistic properties. Their systematic generation combining different classes of compounds from peptides to small molecules has the potential to significantly accelerate drug discovery.
Keywords: Hybrid compounds, prion disease, prions, cell-to-cell transmission, synergistic effects, Creutzfeldt-Jakob disease, Alzheimer's disease.
Current Topics in Medicinal Chemistry
Title:Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Volume: 13 Issue: 19
Author(s): Carsten Korth, Ralf Klingenstein and Andreas Müller-Schiffmann
Affiliation:
Keywords: Hybrid compounds, prion disease, prions, cell-to-cell transmission, synergistic effects, Creutzfeldt-Jakob disease, Alzheimer's disease.
Abstract: An emerging common feature of the age-associated neurodegenerative disorders like Alzheimer's disease (AD) and Creutzfeldt-Jakob disease (CJD) is the ability of many disease-associated protein aggregates to induce conversion of a normal counterpart conformer leading to an acceleration of disease progression. Curative pharmacotherapy has not been achieved so far despite successes in elucidating pathomechanisms. Here, we review the pharmaceutical strategy of generating hybrid compounds, i.e. compounds consisting of several independently acting moieties with synergistic effects, on key molecular players in AD and CJD.
For prion diseases, we review hybrid compounds consisting of two different heterocyclic compounds, their synergistic effects on prion replication in a cell culture model and their ability to prolong survival of experimentally prion-infected mice in vivo. While a combination therapy of several antiprion compounds including quinacrine, clomipramine, simvastatin and tocopherol prolonged survival time to 10-25%, administration of hybrid compound quinpramine alone, a chimera of acridine and iminodibenzyl scaffolds, led to 10% survival time extension.
For AD, we review a hybrid compound consisting of an A recognizing D-peptide fused to a small molecule -sheet breaker, an aminopyrazole. This molecule was able to diminish A oligomers in cell culture and significantly decrease synaptotoxicity as measured by miniature excitatory postsynaptic responses in vitro.
Hybrid compounds can dramatically increase potency of their single moieties and lead to novel functions when they act in a simultaneous or sequential manner thereby revealing synergistic properties. Their systematic generation combining different classes of compounds from peptides to small molecules has the potential to significantly accelerate drug discovery.
Export Options
About this article
Cite this article as:
Korth Carsten, Klingenstein Ralf and Müller-Schiffmann Andreas, Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases, Current Topics in Medicinal Chemistry 2013; 13 (19) . https://dx.doi.org/10.2174/15680266113136660175
DOI https://dx.doi.org/10.2174/15680266113136660175 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sertraline Associated with REM Sleep Behavior Disorder: A Case Report
Current Psychopharmacology An Inflammatory Pathomechanism for Parkinsons Disease?
Current Medicinal Chemistry RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Fluorescent Proteins as Biomarkers and Biosensors: Throwing Color Lights on Molecular and Cellular Processes
Current Protein & Peptide Science Oxidative Stress and Psychological Disorders
Current Neuropharmacology The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Drosophila Models of Proteinopathies: the Little Fly that Could
Current Pharmaceutical Design NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy
Current Pharmaceutical Design Organotypic Hippocampal Slice Cultures for Studies of Brain Damage, Neuroprotection and Neurorepair
Current Drug Targets - CNS & Neurological Disorders Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Aromatherapy and the Central Nerve System (CNS): Therapeutic Mechanism and its Associated Genes
Current Drug Targets Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research Involvement of the Endocannabinoid System in Motor Disorders
Current Medicinal Chemistry - Central Nervous System Agents Joshanda: A Traditional Herbal Approach for Treatment of Respiratory Catarrh
Current Respiratory Medicine Reviews A Possible New Diagnostic Biomarker in Early Diagnosis of Alzheimers Disease
Current Alzheimer Research Docking of Natural Products against Neurodegenerative Diseases: General Concepts
Combinatorial Chemistry & High Throughput Screening The Mitochondrial Unfolded Protein Response: Role in Cellular Homeostasis and Disease
Current Molecular Medicine